ReviewChinese medicine2026
Natural product therapy in diabetic kidney disease: emerging multiomics-mediated signalling pathway and molecular target.
Review in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes, with high mortality and morbidity, and is a major cause of progression to end-stage renal disease (ESRD). Although inhibitors or blockers of renin-angiotensin system blockers have a beneficial effect on the treatment of DKD, most patients progress to ESRD and ultimately require renal replacement therapies. Extensive studies have suggested that natural products, as a mainly new drug source, has been demonstrated to be an important therapy for the prevention and treatment of DKD. Based on genomics, transcriptomics, proteomics and metabolomics technologies, the dysregulation of targeting multiomics-associated gut microbiota, non-coding RNAs, altered proteome and endogenous metabolites has recognized as a promising therapy for DKD. This review summarizes natural products, including traditional Chinese medicine formulas (Qitu Qushi formula, Jin Gui Ren Qi Pill and Huangkui capsules), single herbal extracts (Salvia miltiorrhiza, Korean red ginseng, Abelmoschus manihot flowers) and natural compounds (magnesium lithospermate B, thonningianin A germacrone, triptolide, hesperetin, astragaloside IV, icariin and kaempferol) as well as natural polysaccharides, protect against DKD by regulating novel multiomics-associated molecular mechanisms, including gut microbiota dysbiosis, aberrant non-coding RNAs transcription, and disorder of endogenous metabolites and associated with downstream diverse signals, such as IκB/NF-κB, JAK/STAT, MAPK and NLRP3-mediated inflammation pathways, AGEs/RAGE and Keap1/Nrf2-mediated oxidative stress pathways, PI3K/AKT/mTOR, AMPK and endoplasmic reticulum stress-mediated energy/autophagy pathways and TGF-β/Smad and Wnt/β-catenin-mediated fibrosis pathways. Therefore, the underlying molecular mechanism by which natural products ameliorate DKD by reshaping GM dysbiosis, restoring aberrant expression of ncRNAs and regulating metabolite disorder will provide new therapeutic targets for treatment of DKD of natural products. These findings expand our understanding of therapeutic effects of natural products on DKD and provide valuable information for clinical application of natural products. This review presents a concept-driven therapeutic strategy for DKD treatment and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.